Related Experiment Video
Updated: Jun 26, 2025
04:05
Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment
Published on: May 31, 2024
354
Efficacy and Safety of Ustekinumab for Chronic Pouchitis: A Prospective Open-label Multicenter Study
An Outtier1, Edouard Louis2, Olivier Dewit3
1Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium; Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
Summary
Ustekinumab showed efficacy in treating chronic pouchitis, a complication of ulcerative colitis surgery. This biologic therapy offers a new treatment option for patients with this condition.
Area of Science:
- Gastroenterology
- Inflammatory Bowel Disease
- Clinical Therapeutics
Background:
- Chronic pouchitis affects 17% of patients post-proctocolectomy with pouch surgery for ulcerative colitis.
- Identifying effective treatments for chronic pouchitis is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of ustekinumab in patients with chronic pouchitis.
- To assess steroid-free remission and response rates at 16 and 48 weeks.
Main Methods:
- Prospective study enrolling 22 patients with chronic pouchitis.
- Intravenous and subcutaneous ustekinumab administration over 48 weeks.
- Assessment of Modified Pouchitis Disease Activity Index (mPDAI) at baseline, week 16, and week 48.
Main Results:
- 27.3% of patients achieved steroid-free remission at week 16, and 36.4% at week 48.
- 54.5% achieved clinical response at both weeks 16 and 48.
- Significant reductions in median mPDAI scores (overall, clinical, and endoscopic) were observed by week 48.
Conclusions:
- Ustekinumab demonstrated efficacy in approximately half of the patients with chronic pouchitis.
- Ustekinumab should be considered in the treatment algorithm for chronic pouchitis.
- ClinicalTrials.gov Identifier: NCT04089345.
More Related Videos
Related Concept Videos
01:21Inflammatory Bowel Disease V: Surgical Management
145
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
145
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
113
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
113
01:21Drugs for Treatment of Constipation-Predominant IBS
160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160
01:17Chronic Bowel Disorders: Introduction
445
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
445
01:29Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
01:30Peptic Ulcer Disease I: Introduction
164
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
164